Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Nutrition ; 58: 89-93, 2019 02.
Artigo em Inglês | MEDLINE | ID: mdl-30391696

RESUMO

OBJECTIVE: Home parenteral nutrition (HPN) has become a common therapy, with tunneled central venous catheters (CVCs) being the preferred route of administration. Peripherally inserted central catheters (PICCs) have been used increasingly, but whether they should be preferred over other types of CVCs is still controversial. The aim of this study was to evaluate catheter-related complications of CVC in patients receiving HPN. METHODS: All patients treated at our center for HPN from 2007 to 2017 were prospectively included. A specialized intravenous therapy team took care of these patients. Catheter-related bloodstream infections (CRBSI) were confirmed with positive, simultaneous, differential blood cultures drawn through the CVC and peripheral vein and then semiquantitative or quantitative culture of the catheter tip. RESULTS: In all, 151 patients received HPN during the 11-y study period. Of these patients, 95 were women (63%) and 55 were men (37%), with a mean age of 58 ± 13 y. Twenty-six were non-cancer patients (17%) and the remaining 125 patients had an underlying malignancy (83%). Regarding the CVC, 116 were PICCs, 18 Hickman, and 36 ports. Confirmed CRBSI per catheter-days showed 0.15 episodes per 1000 catheter-days for PICCs, 0.72 for Hickman, and 2.02 for ports. PICCs had less-confirmed CRBSIs per 1000 catheter-days than ports (φ = 0.54, P = 0.005), but no difference between PICCs and Hickman was found (φ = 0.32, P = 0.110). Confirmed episodes of CRBSI (2 versus 13%, χ2 = 6.625, P = 0.036) were more frequent with multilumen catheters. CONCLUSIONS: In our setting, single-lumen PICC and Hickman catheters showed low infectious complications.


Assuntos
Infecções Relacionadas a Cateter/epidemiologia , Cateteres de Demora/microbiologia , Cateteres Venosos Centrais/microbiologia , Nutrição Parenteral no Domicílio/instrumentação , Dispositivos de Acesso Vascular/microbiologia , Estudos de Coortes , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Fatores de Risco
2.
Nutr Hosp ; 35(5): 1005-1008, 2018 Oct 05.
Artigo em Espanhol | MEDLINE | ID: mdl-30307279

RESUMO

INTRODUCTION: intracavitary electrocardiogram (IC-ECG) guidance has been recently proposed for peripherally inserted central catheter (PICC) placement since it may reduce the time of placement and avoid radiological control. OBJECTIVE: to evaluate IC-ECG compared to conventional radiological control. METHOS: prospective study of 532 consecutive patients. Those with arrhythmias or on antiarrhythmic drugs were excluded. In all cases, PICC tip placement was checked by IC-ECG guidance and by a chest X-ray, which was considered as the reference test. RESULTS: PICC placement with IC-ECG guidance was achieved in 96.8% of patients (applicability). PICC correct placement according to IC-ECG guidance was confirmed by chest X-ray in 94% of patients (accuracy). In 13 patients (2.7%) the catheter had to be repositioned after radiological control. The κ concordance index was 0.356 (p < 0.001). The IC-ECG sensitivity was 0.98, with a PPV of 0.97 and a positive likelihood ratio of 1.5. However, the specificity was only 0.35 with a NPV of 0.41 and a negative likelihood ratio of 0.06. CONCLUSION: PICC placement by IC-ECG guidance is plausible, safe, presents adequate indexes of validity and reliability, and allows reducing the time of catheter placement. However, radiological verification is still necessary, especially in cases of negative or uncertain ECG.


INTRODUCCIÓN: recientemente se ha planteado la posibilidad de comprobar la colocación de los catéteres centrales de inserción periférica (PICC) mediante control electrocardiográfico intracavitario (ECG-IC) ya que permitiría disminuir el tiempo de colocación y evitaría el control radiológico. OBJETIVO: evaluación de dicho método frente al control radiológico habitual. MÉTODOS: estudio prospectivo en el que se incluyeron 532 pacientes de forma consecutiva. Se excluyeron aquellos pacientes con arritmias o en tratamiento con fármacos antiarrítmicos. En todos los casos se comprobó la colocación de la punta del PICC mediante control ECG-IC y mediante la realización de una radiografía de tórax, que fue considerada método de referencia. RESULTADOS: la colocación del PICC gracias al control ECG-IC (aplicabilidad) fue del 96,8%. La correcta colocación del PICC gracias a la interpretación del ECG-IC se confirmó en un 94% de los casos con la radiografía de tórax (precisión). En 13 pacientes (2,7%) se requirió la recolocación del catéter tras el control radiológico. El índice κ de concordancia fue de 0,356 (p < 0,001). La sensibilidad del método ECG fue de 0,98, con un VPP de 0,97 y un cociente de probabilidad positivo de 1,5. Sin embargo, la especificidad fue solo del 0,35 con un VPN de 0,41 y un cociente de probabilidad negativo de 0,06. CONCLUSIÓN: la comprobación de la colocación de los PICC mediante ECG-IC es plausible, segura, presenta unos índices de validez/fiabilidad adecuados y permitiría disminuir el tiempo de colocación del catéter. Sin embargo, la comprobación radiológica sigue siendo necesaria, especialmente en los casos de ECG negativo o dudoso.


Assuntos
Cateterismo Venoso Central/métodos , Cateterismo Periférico/métodos , Eletrocardiografia/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Radiografia Torácica , Reprodutibilidade dos Testes , Tórax/diagnóstico por imagem
3.
AIDS ; 17(2): 262-4, 2003 Jan 24.
Artigo em Inglês | MEDLINE | ID: mdl-12545089

RESUMO

Increased drug levels could overcome resistance and improve the response to a salvage regimen. We evaluate the inhibitory quotient (IQ, Ctrough/protein-binding corrected IC50) as a predictor of virological response in 52 patients included in two dual protease inhibitor (PI)-based salvage regimens. The HIV-RNA level decrease at 12 weeks was greater in patients who achieved an IQ greater than 1. The IQ could be useful to improve the virological response to a dual PI salvage regimen.


Assuntos
Infecções por HIV/sangue , Inibidores da Protease de HIV/sangue , HIV-1/efeitos dos fármacos , Farmacorresistência Viral , Quimioterapia Combinada , Infecções por HIV/tratamento farmacológico , Inibidores da Protease de HIV/uso terapêutico , Humanos , Terapia de Salvação
4.
HIV Clin Trials ; 4(1): 21-8, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12577193

RESUMO

PURPOSE: To explore the possibility of overcoming resistance to protease inhibitors (PIs) and to determine the resistance cutoff values that continue to predict treatment failure with a dual PI regimen. METHOD: We performed a prospective study of 53 patients who had failed in several PIs and who were included in a ritonavir (RTV) plus indinavir (IDV) salvage regimen. Median HIV RNA level decrease was evaluated according to resistance assays and indinavir trough levels. RESULTS: Eighty-seven percent of patients had previously failed on an IDV-containing regimen. Overall, median HIV RNA decrease was -1.25 log(10) copies/mL after 3 months on therapy. A significant blunted virologic response was observed only in isolates with more than 12 substitutions including the V82A (-0.75 vs. -1.3 log(10) copies/mL; p =.04), or in isolates with more than 30 fold-increase in the IC(50) (-0.43 vs. -1.2 log(10) copies/mL). Higher drug levels were observed in patients with resistant isolates who achieved an HIV RNA decrease greater than 1 log (1742 vs. 1100 ng/mL). CONCLUSION: Our preliminary data suggest the possibility of overcoming resistance with the combination of RTV plus IDV. They also suggest the need for establishing new resistance cutoff values when using PIs in combination.


Assuntos
Infecções por HIV/tratamento farmacológico , Infecções por HIV/virologia , Inibidores da Protease de HIV/uso terapêutico , Indinavir/uso terapêutico , Ritonavir/uso terapêutico , Terapia de Salvação , Adulto , Farmacorresistência Viral , Quimioterapia Combinada , Feminino , Genótipo , HIV/efeitos dos fármacos , HIV/enzimologia , HIV/genética , Protease de HIV/genética , Inibidores da Protease de HIV/sangue , Humanos , Indinavir/sangue , Masculino , Mutação , RNA Viral/sangue , Ritonavir/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA